But Zydelig (idelalisib) has hit trouble after reports of serious side effects related to compromised immune systems, including several deaths, among patients in studies. The safety concerns ...
Zydelig is authorised in the EU for chronic lymphocytic leukaemia and non-Hodgkin lymphoma. The EMA said the Zydelig combination trials that raised the safety issues were in chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback